Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 9, 2023
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
Thomas Smith Maintained (VRDN) at Buy with Increased Target to $45 on, Jan 9th, 2023
Thomas Smith of SVB Leerink, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Increased Target from $40 to $45 on, Jan 9th, 2023.
Thomas has made no other calls on VRDN in the last 4 months.
There are 4 other peers that have a rating on VRDN. Out of the 4 peers that are also analyzing VRDN, 0 agree with Thomas's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Thomas
- Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $45 on, Monday, December 19th, 2022
- Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $51 on, Friday, December 16th, 2022
- Douglas Tsao of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Thursday, December 1st, 2022
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022
